(8S)-2-氯1,6,7,8-四氢-8-(三氟甲基)-4H-嘧啶并[1,2-A]嘧啶-4-酮 | 1260585-11-2

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: (8S)-2-氯1,6,7,8-四氢-8-(三氟甲基)-4H-嘧啶并[1,2-A]嘧啶-4-酮
• 英文名称: (8S)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one
• 英文别名: (S)-8-chloro-2-(trifluoromethyl)-3,4-dihydro-1H-pyrimido[1,2-a]pyrimidin-6(2H)-one；(8S)-2-chloro-8-(trifluoromethyl)-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one
• CAS: 1260585-11-2
• 化学式: C₈H₇ClF₃N₃O
• 分子量: 253.611
• InChiKey: ISPPUVAQWCTKNO-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (8S)-2-氯1,6,7,8-四氢-8-(三氟甲基)-4H-嘧啶并[1,2-A]嘧啶-4-酮 反应 1.5h， 生成 (8S)-9-(3,5-difluorophenyl)-2-(morpholin-4-yl)-8-(trifluoromethyl)-6,7,8,9-tetrahydro-4H-pyrimido[1,2-a]pyrimidin-4-one
  参考文献：
  名称：

  Discovery of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: A Novel Potent and Selective Inhibitor of Vps34 for the Treatment of Solid Tumors

  摘要：

  Vps34 (the human class III phosphoinositide 3-kinase) is a lipid kinase involved in vesicle trafficking and autophagy and therefore constitutes an interesting target for cancer treatment. Because of the lack of specific Vps34 kinase inhibitors, we aimed to identify such compounds to further validate the role of this lipid kinase in cancer maintenance and progression. Herein, we report the discovery of a series of tetrahydropyrimidopyrimidinone derivatives. Starting with hit compound 1a, medicinal chemistry optimization led to compound 31. This molecule displays potent activity, an exquisite selectivity for Vps34 with excellent properties. The X-ray crystal structure of compound 31 in human Vps34 illustrates how the unique molecular features of the morpholine synthon bestows selectivity against class I PI3Ks. This molecule exhibits suitable in vivo mouse PK parameters and induces a sustained inhibition of Vps34 upon acute administration. Compound 31 constitutes an optimized Vps34 inhibitor that could be used to investigate human cancer biology.

  DOI：

  10.1021/jm5013352
• 作为产物：
  描述：

  4-三氟甲基-2-氨基嘧啶 在 palladium 10% on activated carbon 、 氢气 、 sodium methylate 、 sodium hydroxide 、 三氯氧磷 作用下， 以 甲醇 、 水 、 1,2-二氯乙烷 、 异丙醇 为溶剂， 20.0~100.0 ℃ 、500.01 kPa 条件下， 反应 9.25h， 生成 (8S)-2-氯1,6,7,8-四氢-8-(三氟甲基)-4H-嘧啶并[1,2-A]嘧啶-4-酮
  参考文献：
  名称：

  Pyrimidinone Derivatives as Antimalarial Agents

  摘要：

  这项发明涉及一种新型的嘧啶酮基杂环化合物，这些化合物是寄生虫生长抑制剂，其一般式为（I），其中Y是从三种桥联吗啉中选择的吗啉，L是键或连接物，n=0或1，当n=0时R2是甲基基团，当n=1时是氢原子。其制备方法和治疗用途。

  公开号：

  US20150183804A1

文献信息

• Pyrimidinone Derivatives as Antimalarial Agents
  申请人：SANOFI

  公开号：US20150183804A1

  公开（公告）日：2015-07-02

  The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R 2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

  这项发明涉及一种新型的嘧啶酮基杂环化合物，这些化合物是寄生虫生长抑制剂，其一般式为（I），其中Y是从三种桥联吗啉中选择的吗啉，L是键或连接物，n=0或1，当n=0时R2是甲基基团，当n=1时是氢原子。其制备方法和治疗用途。
• PYRIMIDINONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF
  申请人：Arigon Jerome

  公开号：US20130289031A1

  公开（公告）日：2013-10-31

  The invention relates to novel products of formula (Ia) or (Ib): these products being in all the isomeric forms and salts as drugs, notably as anticancer drugs.

  这项发明涉及公式(Ia)或(Ib)的新产品：这些产品以所有同分异构体和盐的形式作为药物，特别是作为抗癌药物。
• [EN] 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES<br/>[FR] 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YLAMIDES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012085857A1

  公开（公告）日：2012-06-28

  The present invention relates to 3,8-diaza-bicyclo[4.2.0]oct-3-yl amide derivatives of formula (I), wherein the relative configuration of the diazabicyclooctane moiety is cis; and wherein Ar1, and Ar2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及式(I)的3,8-二氮杂双环[4.2.0]辛-3-基酰胺衍生物，其中二氮双环辛烷基的相对构型为顺式；以及其中Ar1和Ar2如描述中所述，其制备方法，其药学上可接受的盐，以及作为药物的用途，含有式(I)一个或多个化合物的药物组合物，特别是其用作促进睡眠激素受体拮抗剂。
• [EN] 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES<br/>[FR] 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YLAMIDES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2012085852A1

  公开（公告）日：2012-06-28

  The present invention relates to 3,8-diaza-bicyclo[4.2.0]oct-8-yl amide derivatives of formula (I) Formula (I) wherein the relative configuration of the diazabicyclooctane moiety is cis; and wherein Ar1, and Ar 2 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的3,8-二氮杂双环[4.2.0]辛基酰胺衍生物。在公式（I）中，二氮杂双环辛烷基的相对构型为顺式；其中Ar1和Ar2如描述中所述，制备方法，其药学上可接受的盐，以及作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是其作为促进睡眠荷尔蒙受体拮抗剂的用途。
• NOVEL 1,2,3,4-TETRAHYDRO-PYRIMIDO(1,2-A)PYRIMIDIN-6-ONE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF
  申请人：Bacque Eric

  公开号：US20120208810A1

  公开（公告）日：2012-08-16

  The invention relates to the novel materials of formula (I), where: R 1 is an optionally substituted L-aryl or L-heteroaryl, such that L is a single bond, alkyl, CO, or CO-alk, or L-X, with L□ being an alkyl and X being O or S; R 2 is H or alkyl; R 3 is an alkyl optionally substituted by Hal; and R 4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.

  本发明涉及式(I)的新型材料，其中：R1是可选取的取代的L-芳基或L-杂环基，L是单键、烷基、CO或CO-烷基，或L-X，其中L□是烷基，X是O或S；R2是氢或烷基；R3是烷基，可选取卤素取代；R4是氢或卤素，所述材料以任何同分异构体形式及其盐形式作为药物。